2nd Circ. Wary Of Anti-Competitive Intent In Namenda Plan

By Melissa Lipman (April 13, 2015, 5:02 PM EDT) -- The Second Circuit worried Monday that an Actavis PLC unit was trying to thwart generic competition by pulling an older version of Alzheimer's treatment Namenda from the market, but judges grilled New York state about where to draw the line between anti-competitive product-hopping and legal use of a patent monopoly....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!